Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 22:e32056.
doi: 10.1002/pbc.32056. Online ahead of print.

Outcomes of Infant Medulloblastoma Treated With Standard-Dose Chemotherapy-A Single-Institution Experience From a Low-Middle-Income Country

Gnanamani Senguttuvan  1 , Leenu Lizbeth Joseph  1 , Rikki Rorima John  1 , Geeta Chacko  2 , Ranjani Jayachandran  2 , Krishna Prabhu  3 , Ranjit K Moorthy  3 , Baylis Vivek Joseph  3 , Rajesh Balakrishnan  4 , Patricia Sebastin  4 , Leni G Mathew  1
Affiliations

Outcomes of Infant Medulloblastoma Treated With Standard-Dose Chemotherapy-A Single-Institution Experience From a Low-Middle-Income Country

Gnanamani Senguttuvan et al. Pediatr Blood Cancer. .

Abstract

Background: Infant medulloblastoma (iMBL) is predominantly desmoplastic nodular (DN) or medulloblastoma with extensive nodularity (MBEN) histology, sonic hedgehog (SHH) driven. Intensified chemotherapy (intraventricular chemotherapy or high-dose chemotherapy with autologous stem cell rescue) is recommended to compensate for the omission of radiation. This study aims to analyze the outcomes of iMBL treated without treatment intensification.

Methods: This retrospective study was performed on 28 patients with iMBL (children with medulloblastoma <3 years at diagnosis or 3-4 years with DN/MBEN histology) treated between January 2004 and April 2024 in a tertiary care institute in southern India.

Results: The median age at diagnosis and duration of symptoms were 24.5 months and 1 month, respectively. Vomiting (82%) and ataxia (71.4%) were the common presentations. Ventriculoperitoneal shunt or endoscopic third ventriculostomy was done in 57% of patients. Twenty-four patients (∼86%) underwent gross/near-total resection. The most common surgical complication was cerebellar mutism (n = 6, 21%). Half of the cohort had nonmetastatic disease. Sixteen patients had DN/MBEN histology. Only 68% (n = 19) opted to continue postoperative treatment. Chemotherapy protocols used were baby SFOP, HIT SKK, and modified Packer. One fourth (n = 7) received radiation (DN/MBEN = 3; other histology = 4) as a part of their initial treatment. There was no treatment-related mortality. The 5-year event-free survival (EFS) of patients who received postoperative chemotherapy ± RT was 70% (those with DN/MBEN were 82.5% and non-DN/MBEN were 35.7%). The 5-year EFS of patients with DN/MBEN histology who received only chemotherapy (n = 9) was 88.9%.

Conclusions: Managing medulloblastoma in infants is challenging in LMIC, as a significant proportion of families opt against postoperative treatment. Although traditionally considered high risk, good survival can be achieved with non-intensified therapy without an increase in treatment-related mortality, especially in patients with DN/MBEN histology.

Keywords: brain tumors; chemotherapy; neuro‐oncology.

PubMed Disclaimer

References

    1. P. A. Northcott, G. W. Robinson, C. P. Kratz, et al., “Medulloblastoma,” Nature Reviews Disease Primers 5, no. 1 (2019): 11.
    1. N. Amayiri, M. Swaidan, A. Ibrahimi, et al., “Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource‐Limited Country,” JCO Global Oncology 7 (2021): GO2100127.
    1. J. Parkes, M. Hendricks, P. Ssenyonga, et al., “SIOP PODC Adapted Treatment Recommendations for Standard‐Risk Medulloblastoma in Low and Middle Income Settings,” Pediatric Blood & Cancer 62, no. 4 (2015): 553–564.
    1. R. Diaz‐Coronado, E. Hernandez‐Broncano, T. Negreiros‐Chinchihuara, et al., “LMIC‐15. Outcomes of Pediatric Medulloblastoma in Low‐ and Middle‐Income Countries: A Report of 330 Patients From 8 Countries,” Neuro‐Oncology 26, no. Suppl 4 (2024), https://doi.org/10.1093/neuonc/noae064.732.
    1. L. V. Baroni, C. Sampor, A. Gonzalez, et al., “Bridging the Treatment Gap in Infant Medulloblastoma: Molecularly Informed Outcomes of a Globally Feasible Regimen,” Neuro‐Oncology 22, no. 12 (2020): 1873–1881.

LinkOut - more resources